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Available online 24 April 2010Background: It is unclear to what extent non-clinical psychotic experiences during childhood
and adolescence share underlying aetiological mechanisms with schizophrenia. One candidate
mechanism for schizophrenia involves the epigenetic status of the developing fetus, which
depends on the internal folate-status of mother and child. Our study examines the relationships
between multiple determinants of perinatal folate-status and development of psychotic
experiences in adolescence.
Methods: Study participants were up to 5344 mother–child pairs from the Avon Longitudinal
Studyof Parents and their Children, UK,with informationonmaternal and/or childMTHFRC677T
genotype, maternal folate intake (supplementation at 18/32- weeks gestation; dietary intake at
32- weeks gestation) and psychosis-like symptoms (PLIKS) for children assessed at age 12.
Results: Nominal evidence was observed that maternal folate supplementation at 18 weeks
increased the odds of PLIKS in children (odds ratio(OR)=1.34; 95%-CI:[1.00;1.76]) and,
consistent with this, that children of MTHFR C667T TT homozygous mothers had decreased
odds of PLIKS (OR=0.72; 95%CI:[0.50;1.02]; recessive model) with strongest effects in boys
(OR=0.44, 95%-CI:[0.22;0.79]; sex-speciﬁc p=0.029). None of the reported effects remained
signiﬁcant when corrected for multiple testing.
Conclusions: Overall, this study found no support that maternal/child MTHFR C677T genotype
and maternal folate intake during pregnancy contribute to common aetiological pathways that
are shared between schizophrenia and non-clinical psychotic symptoms in adolescents,
assuming that decreased folate-status increases schizophrenia risk.
© 2010 Elsevier B.V. Open access under CC BY license. Keywords:
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Epigenetic1. Introduction
Non-clinical psychotic symptoms on interview, including
delusions and hallucinations, have been reported for up to 18%
of adults (Eaton et al., 1991; Johns et al., 2004; Scott et al., 2006;hor. This research was
sity of Bristol.
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Y license. vanOs et al., 2001;Wiles et al., 2006) and 14% of children based
on observer-rated assessment (Poulton et al., 2000). These
proportions exceed by far the life-time cumulative incidence of
any psychotic condition in the general population, which
reaches approximately 2 to 3% (Kendler et al., 1996; Perälä et
al., 2007). The mechanisms linking both psychotic experiences
and schizophrenia are not yet understood.
Findings from the Dunedin cohort suggest the continuity
of psychotic symptoms from childhood to adulthood within a
small proportion of children, such that subclinical psychotic
experiences precede later development of a psychotic
condition (Poulton et al., 2000). This accentuates the
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symptoms share underlying aetiological mechanisms.
A rising body of evidence suggests epigenetic modiﬁcation
as a plausible mechanism that leads to neuropsychiatric
conditions (Bassett et al., 2002) including schizophrenia
(Gräff and Mansuy, 2008). DNA methylation is an important
epigenetic regulator of gene expression, growth and tissue
differentiation (Suzuki and Bird, 2008). It has been hypothe-
sised that aberrant DNA methylation might be implicated
within the aetiology of psychotic disorders through abnormal
neurodevelopment (Singh et al., 2003) or high-risk concep-
tions (Jongbloet et al., 2008).
The ﬁdelity of DNA methylation patterns crucially depends
on the regulation of the folate- and one-carbon-cycle (McNulty
and Scott, 2008). One of the key players in this cycle is
methylenetetrahydrofolate reductase (MTHFR). This enzyme
reduces 5,10-methylene tetrahydrofolate (THF) irreversibly
into 5-methyl THF, themethyl-group donor for the remethyla-
tion of homocysteine (Hcy) intomethionine (Frosst et al., 1995;
Selhub, 2002). A common nonsynonymousMTHFR variant has
been identiﬁed (C677T; rs1801133), which leads to a thermo-
labile mutant protein with 30% lower enzyme activity in vitro
(Frosst et al., 1995). The MTHFR 677T allele has been linked to
increasedplasma totalHcy levels (Frosst et al., 1995),which are
responsible for the inhibition of the methylation reaction
(James et al., 2002). Highest Hcy-levels were observed for TT
homozygotes under impaired folate-status (Brattström et al.,
1998; Friso et al., 2002).
MTHFR C677T variation has been related to a wide
spectrum of phenotypes including neural tube disorders
(NTD; Blom et al., 2006) and cognition (Roffman et al., 2008).
Evidence from recent meta-analyses on schizophrenia sug-
gested thatMTHFR 677T, in particular the TT genotype (Lewis
et al., 2005; Gilbody et al., 2007), confers susceptibility to
psychosis, although there appears to be considerable study
heterogeneity (Allelic odds ratio (OR): I2=52% to 57%; Allen
et al., 2008; Shi et al., 2008).
Within the developing child the internal folate status is also
inﬂuenced by nutritional exposures, particularly in utero and
during early postnatal development (Waterland and Michels,
2007), andadeﬁciencyof dietary folatehasbeenassociatedwith
impaired DNA methylation (Friso et al., 2002). Low internal
folate-status has been suggested as a risk factor for cognitive
impairment (Ramos et al., 2005) and appears to contribute to
the aetiology of neural tube disorders (NTD; Blom et al., 2006).
The latter is of particular interest as NTD and schizophreniamay
shareunderlying risk factors (Zammit et al., 2007) strengthening
positions which implicate folate-status within the aetiology of
psychosis (Davey Smith and Ebrahim, 2003).
Our study aimed to investigate relationships between
non-clinical psychotic symptoms in adolescence and key
determinants of fetal folate-status, including maternal folate
supplementation and dietary folate intake during pregnancy,
as well as maternal and child MTHFR C677T genotypes.
2. Materials and methods
2.1. Sample description
ALSPAC is a population-based prospective birth cohort with
extensive data collection on health and development ofchildren and their parents. All pregnant women in the Bristol
area (England) with an expected delivery between April 1991
and December 1992 were eligible and approached for partic-
ipation. 14541 women enrolled within the study and 13988
children were alive at one year. A detailed description of the
cohort has been published previously (Golding et al., 2001).
Ethical approval was obtained from the ALSPAC Law and Ethics
Committee and the Local Research Ethics Committees.
2.2. Measurement of folate intake
Three measures of maternal folate intake during pregnancy
were investigated in this study as their effects may vary during
the course of embryogenesis inﬂuencing different aspects of
fetal epigenetic re-programming and modiﬁcation (Dolinoy
et al., 2007). Maternal folate supplementation at 18 and 32-
weeks gestation was assessed using questionnaire data and
based on whether supplements had been taken within the last
3 months.Maternal dietary folate intake (g/week) at 32-weeks
gestation, excluding supplements, was measured using food
frequency questionnaires (FFQ). For statistical analysis, dietary
intake was converted into Z-scores.
Both measures of folate supplementation were correlated
with each other (product-moment correlation-coefﬁcient:
ρ=0.43; pb0.001) but onlymarginally related to dietary folate
intake (biserial correlation-coefﬁcient: 0.060bρ≤0.080;
0.016bp≤0.04).
2.3. Measurement of psychotic symptoms
Non-clinical psychotic symptoms in children were mea-
sured at the age of 12 using the semi-structured psychosis-like
symptoms (PLIKS) interview (Horwood et al., 2008) consisting
of 12 core questions covering the past 6-month occurrence of
hallucinations, delusions and experiences of thought interfer-
ence. All items followed the glossary deﬁnitions of the
Schedules for Clinical Assessment in Neuropsychiatry (Wing
et al., 1990). Symptoms were rated as either not present,
suspected or deﬁnitely present (average-interrater-reliability:
κ=0.72). Present symptomswere only included in the score if
not attributable to sleep, fever or substanceuse. PLIKS cases and
controls were deﬁned through presence or absence of deﬁnite
or suspected PLIKS symptoms respectively.
2.4. Measurement of potential confounders
During the antenatal period information on potential
confounders was obtained: maternal parity (0, 1, 2, or 3+)
and age at birth of the study child, maternal cigarette smoking
(‘No’, ‘Yes’) and alcohol consumption (‘Never’, ‘less than 1
glass per week’, ‘more than 1 glass per week’) during the ﬁrst
three months of pregnancy, maternal family history of
depression (mother reporting on herself or her parents as
suffering from depression; ‘No’, ‘Yes’); maternal education
(‘BelowO-level’, ‘O-level’ and ‘Above O-level’; O-levels are UK
school-leaving qualiﬁcations taken at age 16), occupational
social class (lower of either maternal or paternal social class;
‘Non-Manual’ and ‘Manual’; Dale and Marsh, 1993) and
housing tenure (‘Mortgaged or owned’, ‘Privately rented’,
‘Council or Housing authority or Other’).
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DNA was extracted as previously described (Jones et al.,
2000). Genotyping of maternal and child DNAwas performed
by KBioscience Ltd. (www.kbioscience.co.uk) using a com-
petitive allele-speciﬁc PCR system (KASPar). Genotypes in
mothers (Mothers of cases: p=0.11; mothers of controls:
p=0.86) and children (cases: p=0.49; controls: p=0.63)
were in adherence to Hardy–Weinberg equilibrium, reaching
a call rate of 95.2% and 93.8% respectively.
2.6. High-risk folate deﬁciency score
Folate-related nutritional and genetic information during
early fetal life were also integrated into a high-risk folate
deﬁciency score. For each single risk factor of folate deﬁciency
present (i.e. no maternal folate supplementation at either 18
or 32 weeks, or a maternal dietary folate intake of one
standard deviation (SD) below average at 32 weeks, or a
maternal or child MTHFR C677T TT genotype), the score was
increased by one (range 0 to 5).
2.7. Statistical methods
Associations between PLIKS and determinants of perinatal
folate-status were assessed with logistic regression models
and adjusted for sex (crude models). Models involving
maternal folate intake were additionally adjusted for poten-
tial confounders as described above (adjusted models). Effect
moderation, including sex-speciﬁc effects, maternal–child
genotype and maternal folate -genotype interactions, was
assessed with likelihood ratio tests (LRTs). Adherence of
genotypes to Hardy–Weinberg-equilibrium was investigated
with exactχ2-tests (Wigginton et al., 2005). All analyseswere
performed with the R software (CRAN, 2008).
To account for the possibility of unequal genotyping drop-
out, sensitivity analyses was performed by comparing PLIKS
cases and controls according to their expected parental
mating type thus allowing for non-random genotype dis-
tributions. As parental mating types cannot be unequivocally
derived from mother–child dyad information, case and
control-speciﬁc mating type frequencies were estimated
from the observed mother–child dyad frequencies using a
simple Bayesian model (WinBUGS; Lunn et al., 2000; for
details see Online supplement). Estimated mating type
counts in cases and controls were formally compared using
χ2-tests (see Online supplement Table 2).
3. Results
3.1. Sample selection
3.1.1. Nutrient sample
Among 13,988 eligible singleton one-year-survivors and
13617 eligible mothers, who gave birth to a one-year
surviving singleton child, there were 5344 mother–child
pairs (38.2% eligible children; 39.2% eligible mothers) of
White European origin with information on maternal folate
intake and potential confounders during pregnancy, and
PLIKS in children.3.1.2. Child MTHFR C677T sample
MTHFR C677T genotypes were available in 8645 indivi-
duals (61.8% eligible children). 4780 (34.17%) of these had
data on PLIKS and were of White origin.
3.1.3. Maternal MTHFR C677T sample
MTHFR C677T was successfully genotyped in 8069 (59.3%)
eligible mothers. 4109 (30.2%) of these had children, who
were assessed for the presence of PLIKS and 3943 of those
mother–child pairs were of White origin (29.0% eligible
mothers; 28% eligible children).
3.1.4. Nutrient–genotype interaction sample
2845 mother–child pairs (20.9% eligible mothers, 20.3%
eligible children) had complete information on maternal and
child MTHFR C677T genotypes, maternal folate intake during
pregnancy, PLIKS in children and potential confounders.
Characteristics for each sample are given in Table 1.
The prevalence of ALSPAC children with deﬁnite/sus-
pected PLIKS within this study was approximately 10 to 11%
(see Table 1). This is lower than previously reported ﬁgures
on the same cohort (Horwood et al., 2008).
3.2. Association between maternal folate intake during
pregnancy and PLIKS
The relationship between maternal folate intake during
pregnancy and PLIKS in children was investigated using the
most complete phenotypic information available (nutrient
sample, see Table 2).
There was no evidence that an overall high-risk folate
deﬁciency score during pregnancy was related to PLIKS
(Nutrient sample; 0.13bp≤0.59, adjusted model, see
Table 2). As the effects of folate deﬁciency however may
depend on the embryogenetic phase (Dolinoy et al., 2007),
we also examined the effects of nutritional folate intake at
32 weeks and folate supplementation at 18 and 32 weeks.We
observed that maternal folate supplementation at 18 weeks
nominally increased the odds for PLIKS in children
(OR=1.34; 95%CI: [1.00;1.76]; p=0.047, adjusted model),
but found no effects for folate supplementation and dietary
folate intake during later pregnancy.
3.3. Association between MTHFR C677T and PLIKS
The association between PLIKS and MTHFR C677T in
mothers and children respectively was studied by exploiting
all available genetic information (Child and maternal MTHFR
C677T sample, see Table 3). A recessive genetic model was
assumed as this model showed superior model ﬁtting in
particular for maternal genotype effects (Recessive: Akaike
information criterion (AIC)=2595; log-additive: AIC=2598),
although this was less pronounced for child genotype effects
(Recessive: AIC=3310; log-additive: AIC=3310). Genetic
association analysis identiﬁed a trend for an association
between maternal MTHFR C667T and PLIKS such as that
children of homozygous TT mothers showed 0.72 lower odds
(95%-CI: [0.50;1.02]) of expressing these symptoms than
children of CC/TC mothers. This effect appeared to be sex-
speciﬁc (p=0.029) and was observed in boys only (OR=0.44,
95%-CI: [0.22;0.79]). There was no evidence for a relationship
Table 1
Sample descriptions.
M C667T — Maternal MTHFR C677T; C C677T — Child MTHFR C677T; FS18/FS32 — Folate supplementation at 18- and 32-week gestation; Folate — Maternal
dietary folate intake at 32 weeks gestation; Low/Medium/High Folate — Low (intake≤mean−one SD), medium (mean−one SDb intakebmean+one SD )
or high (mean+one SD≤ intake) (Categorisation for descriptive analysis only); SD — Standard deviation.
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genotype effects (p=0.62). There was also no support for a
maternal or childMTHFR C667 genotype effect when assuming
an underlying log-additive genetic disease model (data not
shown).
3.4. Effect moderation of folate-related risk factors for
schizophrenia and PLIKS
Interactions between genetic and environmental deter-
minants of fetal folate-status were explored using the smaller
nutrient–genotype interaction sample (see online Supple-
ment Table 1). The main effects for MTHFR C677T and
maternal folate intake in this restricted sample were
consistent with those reported above, although the conﬁ-
dence intervals were wider, and none of the results
approached signiﬁcance (see online Supplement Table 1).
Maternal folate intake effects did not vary with regard to
genetic MTHFR background (interaction with maternal
genotype: 0.34bp≤0.37; interaction with child genotype:
0.060bpb0.56, adjusted model). A trend for an interaction
was observed between folate supplementation at 32 weeks
and child MTHFR C677T (p=0.060, adjusted model).There was no evidence for a trans-generational MTHFR
mother–child interaction (p=0.46; crude model, data not
shown) and no support was found for a combined effect of
genetic and dietary/supplementary risk factors of folate
deﬁciency (High-risk folate deﬁciency score: OR=0.95, 95%
CI: [0.78;1.15]).
3.5. Adjustment for multiple testing
Assumingat least three independent tests (formaternal/child
MTHFR C677T genotype, maternal folate supplementation at 18
and 32- weeks gestation, and maternal dietary folate intake at
32- weeks gestation), there was no evidence for an overall
association betweendeterminants of fetal folate status andPLIKS
in children at age 12 after Bonferroni-correction, or for overall
interaction effects including sex-speciﬁc effects (although the
number of performed interactions tests was much higher).
3.6. Population genotype distribution of MTHFR C677T
MTHFR C677T genotype distributions might be distorted
as a result of unequal sample drop-out or random ﬂuctuation
due to small sample numbers. Mating type-frequencies were
Table 2
Association between maternal folate intake during pregnancy and PLIKS.
Unadjusted Adjusted
OR [95% CI] P PSex OR [95% CI] P PSex
All (N=5344, Cases=592)
FS18 a 1.31 [0.99;1.72] 0.063 0.37 1.34 [1.00;1.76] 0.047 0.38
FS32 a 1.08 [0.87;1.33] 0.49 0.23 1.11 [0.90;1.38] 0.32 0.26
Folate b 0.99 [0.91;1.09] 0.89 0.13 1.03 [0.93;1.12] 0.60 0.19
Folate deﬁciency c 0.99 [0.81;1.20] 0.89 0.53 0.92 [0.75;1.12] 0.40 0.71
Boys (N=2613, Cases=280)
FS18 a 1.49 [1.00;2.17] 0.052 – 1.50 [1.00;2.19] 0.051 –
FS32 a 1.22 [0.91;1.63] 0.18 – 1.22 [0.90;1.64] 0.19 –
Folate b 1.07 [0.94;1.22] 0.32 – 1.08 [0.95;1.24] 0.23 –
Folate deﬁciency c 0.92 [0.69;1.23] 0.58 – 0.90 [0.67;1.20] 0.48 –
Girls (N=2731, Cases=312)
FS18 a 1.15 [0.76;1.69] 0.48 – 1.19 [0.78;1.75] 0.40 –
FS32 a 0.95 [0.69;1.27] 0.72 – 0.99 [0.72;1.35] 0.97 –
Folate b 0.93 [0.82;1.05] 0.25 – 0.97 [0.86;1.11] 0.69 –
Folate deﬁciency c 1.05 [0.80;1.37] 0.74 – 0.93 [0.71;1.22] 0.60 –
Models were adjusted for potential maternal confounders (parity, age at birth of the study child, cigarette smoking and alcohol consumption during the ﬁrst three
months of pregnancy, family history of depression, education), occupational social class, housing tenure and offspring sex (complete sample only).
FS18/FS32 — Folate supplementation at 18 or 32- weeks gestation; OR — Odds ratio; Folate — Maternal dietary folate intake at 32 weeks gestation; Folate
deﬁciency — High-risk folate deﬁciency score; PSex — Sex speciﬁc effect; SD — Standard deviation.
a ORs are given for presence vs. absence of folate supplementation.
b ORs are given for an increase in one SD of dietary folate intake.
c ORs are given for an increase in one score unit.
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Bayes approach (gene-nutrient interaction sample, see
Online Supplement) but showed only marginal deviation
from Hardy–Weinberg expected frequencies (∼2%) for some
mating type probabilities (see Online Supplement Table 2).
There was no evidence for differences in mating type
frequencies when comparing estimated counts between
cases and controls (χ2(5)=1.16, p=0.94).
4. Discussion
This study investigated the association between markers
of folate-status in utero and risk of developing psychotic
symptoms at age 12. Our analyses focused on the direct and
moderating inﬂuences of maternal folate supplementation
assessed at 18 and 32- weeks gestation, maternal dietary
folate intake at 32- weeks gestation and maternal and child
MTHFR C667T genotypes.Table 3
Association between MTHFR C677T and PLIKS.
Genotype Sample N Cases OR [95% CI] a P PSex
M C677T All 3943 401 0.72 [0.50;1.02] 0.062 0.029
Boys 1950 194 0.44 [0.22;0.79] 0.0041 –
Girls 1993 207 1.00 [0.63;1.53] 0.99 –
C C677T All 4780 524 1.02 [0.76;1.35] 0.89 0.62
Boys 2396 253 1.10 [0.72;1.62] 0.66 –
Girls 2384 271 0.95 [0.62;1.40] 0.80 –
Models were adjusted for offspring sex (complete sample only).
M C667T — Maternal MTHFR C677T; C C677T — Child MTHFR C677T; PSex —
Sex speciﬁc effect; OR — Odds ratio.
a ORs are given for TT vs CC/TC genotypes.Overall, we found no support for the hypothesis that
determinants of impaired perinatal folate-status increase risk
of non-clinical psychotic symptoms, as is commonly hypothe-
sised for schizophrenia. There was nominal evidence for
higher odds of PLIKS in childrenwhenmothers supplemented
their diet with folate early during pregnancy (18 weeks).
These results were consistent in their direction of association
with the observed maternal MTHFR C677T effect (recessive
model only); in particular boys had lower odds of expressing
PLIKS when their mothers carried the TT genotype, which is
associated with lower folate-status (Brattström et al., 1998;
Friso et al., 2002). However, there was no evidence that the
studied risk factors acted jointly or through gene-nutrient
interactions, and none of the reported overall ﬁndings was
signiﬁcant when adjusted for multiple testing. Although
observed associations for folate supplements at 18 weeks
and maternal TT genotypes may suggest risk effects of higher
fetal folate-status, especially in boys, they are likely to re-
present chance ﬁndings.
The power of our study to detect genetic and environ-
mental effects was good to excellent. For example, within
the Child MTHFR C667T sample the power approached 75%
(recessive model) to approximately 100% (log-additive
model) to detect a moderate recessive (OR=1.44)(Gilbody
et al., 2007) or log-additive genotype-risk effect respectively
assuming a MTHFR 677T allele frequency of 0.33 and a PLIKS
population risk of 10% (Gauderman and Morrison, 2006).
Likewise, the power to detect a protective folate supplement
effect (OR=0.70) within the nutrient sample, assuming for
example a 24% prevalence of maternal folate supplementa-
tion, as observed at 32 weeks, was high (91%). In view of the
inherent study power, it is therefore unlikely that we have
missed genetic or dietary/supplement effects that relate to
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hypothesised for schizophrenia. Their absence however
might be related to several reasons: First, the relationship
between internal folate-status and mental health outcomes
at age 12 is likely to be complex. This may involve
interactions between MTHFR C677T genotype and folate
status (Brattström et al., 1998; Friso et al., 2002) but also
between folate and other key determinants of the folate
cycle such as those that are regulated by vitamin B12 (e.g.
Selhub et al., 2009). However, our power to detect effect
moderation was low. Assuming an alleviation of the
genotype risk through folate supplementation (OR=0.50)
and otherwise similar conditions for a recessive genetic
effect as outlined above, our interaction sample had only
25% power to detect gene–nutrient interactions (Gauderman
and Morrison, 2006). Second, the effect of folate intake
during pregnancy may depend on the embryogenetic phase
as the epigenetic architecture of the fetal genome is
established during time-sensitive periods (Dolinoy et al.,
2007). It is therefore possible that the effect of fetal folate
status on later mental health outcome varies during the
course of the embryonic development and that our
measures of maternal folate intake were inadequate at
measuring the true exposure during these speciﬁc periods.
Third, it is not clear to what extent non-clinical psychotic
symptoms as assessed in this study reﬂect the same
pathology underlying chronic and severe psychotic disor-
ders such as schizophrenia. Although most established risk
factors for schizophrenia also show associations with non-
clinical psychotic experiences (Schreier et al., 2009; van Os
et al., 2009; Zammit et al., 2009), ﬁndings across these
phenotypes are not always consistent (Zammit et al., 2008).
Our ﬁndings may therefore have relevance for studying the
aetiology of non-clinical psychotic symptoms during child-
hood and adolescence, and contribute to the identiﬁcation of
risk factors that distinguish psychosis-like symptoms from
schizophrenia. Fourth, we had no direct measure of folate
exposure in utero. Although both, nutrition scores based on
self-reported FFQs (Kleiser et al., 2009) and MTHFR
genotypes (Frosst et al., 1995), have been related to
serum/plasma homocysteine levels, misclassiﬁcation will
be present to some extent. This may have led to under-
estimating associations if misclassiﬁcation is assumed to be
non-differential with respect to psychotic symptoms, as
seems most probable.
No evidence was found for bias due to non-random
genotyping dropout when examining differences in estimated
mating-type probabilities in PLIKS cases and controls. MTHFR
C667T genotype distributions are furthermore unlikely to be
confounded through socio-economic factors (Davey Smith and
Ebrahim, 2003). Nonetheless, residual confounding remains a
possibility that may have affected the selected measures of
folate supplementation and dietary intake although our
analyses were adjusted for a wide range of confounders
including maternal parity, maternal cigarette smoking and
alcohol consumption during the ﬁrst three months of preg-
nancy, maternal family history of depression, maternal educa-
tion, occupational social class, and housing tenure.
In conclusion we found no evidence that markers of folate
status in utero were associated with risk of developing
psychotic symptoms in adolescence.Role of the funding source
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